H3Africa is developing capacity for health-related genomics research in Africa

Background. Blood pressure (BP) control is poor among hypertensives in many parts of sub-Saharan Africa. A potentially modifiable factor for control of BP is medication nonadherence (MNA); our study therefore aimed to determine factors associated with MNA among hypertensives in Ghana and Nigeria. Methodology. We conducted a multicenter cross-sectional study. Patients were recruited from Korle-Bu Hospital (n = 120), Ghana; and University of Port Harcourt Teaching Hospital, (n = 73) Apapa General Hospital Lagos (n = 79) and University College Hospital Ibadan (n = 85), Nigeria. Results. 357 hypertensive patients (42.6% males) participated. MNA was found in 66.7%. Adherence showed correlation with depression (r = −0.208, P < 0.001), concern about medications (r = −0.0347, P = 0.002), and knowledge of hypertension (r = 0.14, P = 0.006). MNA was associated with formal education (P = 0.001) and use of herbal preparation (P = 0.014). MNA was found in 61.7% of uninsured participants versus 73.1% of insured participants (P = 0.032). Poor BP control was observed in 69.7% and there was significant association between MNA and poor BP control (P = 0.006). Conclusion. MNA is high among hypertensives in Ghana and Nigeria and is associated with depression, concern about hypertensive medications, formal education, and use of herbal preparations. The negative association between health insurance and MNA suggests interplay of other factors and needs further investigation.

The burden of tuberculosis (TB) especially in developing countries continues to remain high despite efforts to improve preventive strategies. Known traditional risk factors for TB include poverty, malnutrition, overcrowding, and HIV/AIDS; however, diabetes, which causes immunosuppression, is increasingly being recognized as an independent risk factor for tuberculosis, and the two often coexist and impact each other. Diabetes may also lead to severe disease, reactivation of dormant tuberculosis foci, and poor treatment outcomes. Tuberculosis as a disease entity on the other hand and some commonly used antituberculous medications separately may cause impaired glucose tolerance. This review seeks to highlight the impact of comorbid TB and diabetes on each other. It is our hope that this review will increase the awareness of clinicians and managers of TB and diabetes programs on the effect of the interaction between these two disease entities and how to better screen and manage patients.

No abstract

The goal of this study was to determine the effect of CYP2B6 genetic variation on the steady-state pharmacokinetics of efavirenz (600 mg/day) in TB/HIV co-infected patients receiving concomitant rifampin, a potent CYP inducer. In the 26 patients studied, CYP2B6 c.516GG, GT and TT genotype frequencies were 0.27, 0.50 and 0.23, respectively. Mean plasma efavirenz area-under-the-curve was significantly higher in patients with CYP2B6 c.516TT than in those with GT (107 vs. 27.6 μg.h/mL, P < 0.0001), or GG genotype (107 vs. 23.0 μg.h/mL, P < 0.0001). Apparent oral clearance (CL/F) was significantly lower in patients with CYP2B6 c.516TT than in those with GT genotype (2.1 vs. 8.4 mL/min/kg, P < 0.0001), and GG genotype (2.1 vs. 9.9 mL/min/kg, P < 0.0001). No differences in efavirenz exposure or CL/F existed between patients with CYP2B6 c.516GT and GG genotypes. Our results indicate that CYP2B6 c.516TT genotype can be used to identify efavirenz poor metabolizers in patients co-treated with rifampin. KeywordsCytochrome P450 2B6; genetic polymorphisms; efavirenz exposure; rifampin Tuberculosis (TB) is the most common complication of human immunodeficiency virus (HIV) infection and is associated with high fatality rates. 1,2 While highly active antiretroviral therapy (HAART) improves survival in co-infected patients, 3-5 potential overlapping drug toxicities, and cytochrome P450 (CYP)-mediated drug-drug interactions constitute major challenges to early initiation of HAART. The magnitude of drug-drug interactions due to rifampin is a major factor in selecting an effective HAART regimen. 6-8 Rifampin is a critical component of TB therapy, 9 but is also a potent inducer of CYP enzyme activity, 10-12 as well as the Pglycoprotein (P-gp) transport system. 13 As a result, the exposure to the HIV protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) is reduced during Currently, it is not known whether CYP induction by rifampin will affect the relationship between CYP2B6 c.516G>T genotype and efavirenz exposure. The reported magnitude of induction of CYP2B6 activity by rifampin in primary human hepatocytes varies. While some authors reported a 7 − 13-fold induction, 10,11 others found only 2.5-fold increase in activity. 12 In one in vivo study, CYP2B6 activity in the presence of rifampin was only 2.1 times that in the absence of rifampin. 23 Co-administration of rifampin with efavirenz 600 mg daily caused a 22% reduction in efavirenz area under the curve (AUC) in HIV/TB co-infected patients, which was overcome by increasing the dose to 800 mg/day. 24 This finding led some experts to recommend an increased efavirenz dose when co-administered with rifampin. 6,7,25 Although an increased efavirenz dose might be appropriate for some persons, it does not take into consideration the variable effect of rifampin on CYP2B6 activity. In the aforementioned pharmacokinetic study, the change in efavirenz AUC with concomitant rifampin ranged from a decrease of 65% to an increase of 37%. 24 Furthermore, vari...

Background. Type 2 diabetes mellitus (T2DM) is a major public health problem associated with distress. T2DM can affect health outcomes and adherence to medications. Little is however known about the association between diabetes distress and medication adherence among patients with T2DM in Ghana. Objective. The objective of the present study is twofold: to estimate distress associated with T2DM and to examine its association with medication adherence. Methods. A hospital-based crosssectional study was conducted among 188 patients with T2DM recruited from a diabetes specialist outpatient clinic at the Pantang Hospital in Accra, Ghana. Data were obtained using the Problem Areas In Diabetes (PAID) scale and the Medication Adherence Report Scale. Results. The findings showed that about 44.7% of the patients showed high levels of diabetes-related distress. Poor adherence to medications was recorded in 66.5% of the patients. Patients who were highly distressed had 68% lower odds of adhering to their medications compared to those who were not (OR: 0.32, 95% CI: 0.15-0.65). A principal component analysis revealed four areas of T2DM distress which were conceptualized as negative emotions about diabetes, dietary concerns and diabetes care, dissatisfaction with external support, and diabetes management helplessness. Conclusion. Our findings suggest that diabetes distress is a significant determinant of medication adherence behaviour in patients with T2DM. Thus, incorporating routine screening for distress into the standard diabetes care within the Ghanaian health system and having health practitioners adopt holistic approaches to diabetes management will be important context-specific interventions to improve adherence and health outcomes of people living and coping with T2DM.

Not indicayed.

No abstract